CORT insider files Form 144 after option exercise — 20,000 shares via Stifel

Rhea-AI Filing Summary

Form 144 filed for Corcept Therapeutics, Inc. (CORT) proposes the sale of 20,000 common shares through Stifel Nicolaus & Co. on 09/02/2025. The shares were acquired the same day via stock option exercise and payment was in cash. The filing identifies the seller as Sean Maduck, who reported multiple share sales in the prior three months totaling 60,000 shares and gross proceeds of $4,321,783.00. The proposed sale lists an aggregate market value of $1,394,400.00 and indicates the issuer's shares outstanding as 105,370,000. The notice includes the seller's attestation about absence of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider sale filing; 20,000 shares proposed after a same-day option exercise, following 60,000 shares sold in prior three months.

This Form 144 documents a planned resale of 20,000 Corcept common shares executed via Stifel on 09/02/2025. The shares were acquired by exercise of options and paid in cash the same day, indicating a standard liquidity event rather than a corporate financing or capital-raising action. Prior reported dispositions by the same person over the past three months total 60,000 shares with gross proceeds of $4.32 million, showing ongoing monetization of holdings. From a market-impact perspective, the proposed block equals roughly 0.019% of the reported 105.37 million outstanding shares, suggesting limited dilution or immediate market pressure from this single filing.

Corporate Governance Expert

TL;DR: Insider exercised and is selling stock under Rule 144; filing contains standard attestation about material nonpublic information.

The filing follows Rule 144 reporting requirements: it discloses acquisition method (stock option exercise), intended broker, and sale timing. The seller's attestation that no undisclosed material adverse information exists is typical and necessary for compliance. Repeated recent sales by the same individual are disclosed, which is important for transparency on insider liquidity. There is no indication in this document of any change in senior management, related-party transactions beyond the sales, or other governance events.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Co. Inc. 501 N. Broadway St. Louis MO 63102	20000	1394400.00	105370000	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Stock Option Exercise	Corcept Therapeutics Inc.			20000	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	06/02/2025	20000	1581686.00
Sean Maduck 101 Redwood Shores Parkway Redwood Ciity CA 94065	Common	07/01/2025	205	15058.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/17/2025	4315	317054.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/18/2025	473	34747.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	08/01/2025	35007	2373238.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Corcept Therapeutics (CORT) Form 144 filed on 09/02/2025 disclose?

The filing discloses a proposed sale of 20,000 common shares via Stifel Nicolaus on 09/02/2025, acquired the same day by stock option exercise and paid in cash.

Who is the seller named in the Corcept Form 144 and what recent sales are reported?

The seller is named as Sean Maduck. The filing lists five prior sales in the past three months totaling 60,000 shares with gross proceeds of $4,321,783.00.

How large is the proposed sale relative to Corcept's outstanding shares?

The proposed 20,000-share sale is shown against 105,370,000 shares outstanding, representing approximately 0.019% of shares outstanding as reported in the filing.

What acquisition method and payment were used for the shares to be sold?

The shares were acquired by stock option exercise on 09/02/2025, and the filing indicates cash as the payment method.

Which broker is named to execute the planned sale in the Form 144?

The broker listed is Stifel Nicolaus & Co. Inc., 501 N. Broadway, St. Louis, MO and the exchange named is NASDAQ.